Get 50% OFF This Monsoon!

Advertisement
AdvertisementAdvertisement
logo

Bliss GVS Pharma

BLISSGVS
Small Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement
AdvertisementAdvertisement

Bliss GVS Pharma Share price and Fundamental Analysis

View All Details
View All Details
Bliss GVS Pharma Ltd is an export-oriented pharmaceutical company. It is among the world leaders in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment. Bliss GVS Pharma has presence in antimalarial, antifungal, antibacterial, anti-inflammatory and antibiotic therapeutic segments. It is a leading player in the antimalarial branded formulations segment. Bliss GVS Pharma is the only EU-GMP certified suppositories manufacturer in India.
Company Incorporation1984
ChairmanSubramanian R Vaidya
Head QuartersMumbai
Previous NameNA

Key Metrics

Market Cap (Cr)
1,565.8
PE Ratio
18.58
Industry P/E
35.21
PEG Ratio
1.69
ROE
8.03%
ROCE
11.75%
ROA
6.94%
Total Debt (Cr)
67.72
Debt to Equity
0.08
Dividend Yield
0.34%
EPS
8
Book Value & P/B
100.47 x 1.48
Face Value
1
Outstanding Shares(Cr)
10.54
Current Ratio
7.11
EV to Sales
1.78

Included In

+More

Stock Returns

1 Week+6.37%
1 Month+25.2%
6 Months-15.78%
1 Year+40.23%
3 Years+100.72%
5 Years+48.95%

CAGR

1 Year CAGR

Revenue Growth

+2.48%

Net Profit Growth

+6.31%

Operating Profit Growth

+11.14%

Dividend Growth

0%

Stock Returns CAGR

+43.12%
no_data

No Stocks

Smart Score

2.9
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

/ View Standalone
PARTICULARS

Total Revenue

Total Expenses

Operating Expense

Operating Profit

Interest

Depreciation & Amortization

Profit Before Tax

Tax

Profit after tax

Adj EPS in Rs - Basic

Adj EPS in Rs - Diluted

Profit and Loss Statement

/ View Standalone
Credit Rating
Director Report
Chairman Report
Auditor Report

Balance sheet

/ View Standalone

Cashflow Statement

/ View Standalone
Mar 25

Promoters : 35.29%

FIIs : 13.18%

DIIs : 6.55%

Public : 44.98%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in March 2025 Qtr
Promoter Shareholding Increased by 0.19% to 35.29% in March 2025 Qtr
FII Shareholding Decreased by 0.33% to 13.18% in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Bliss GVS Pharma Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Bliss GVS Pharma Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Bliss GVS Pharma Ltd is an export-oriented pharmaceutical company. It is among the world leaders in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment. Bliss GVS Pharma has presence in antimalarial, antifungal, antibacterial, anti-inflammatory and antibiotic therapeutic segments. It is a leading player in the antimalarial branded formulations segment. Bliss GVS Pharma is the only EU-GMP certified suppositories manufacturer in India.

The company has a dedicated the R&D Centre for development of Suppositories, Semi Solids and Oral Solids with an experienced Team of over 50 Scientists for formulation development and analytical method development and certified by the Department of Scientific & Industrial Research (DSIR), Government of India.

Incorporated in 1984 as a private limited company under the name Bliss Chemicals & Pharmaceuticals India Ltd, the company commenced its business in 1985. In 1994 the company introduced a new pharmaceutical product VAGID.During the financial year ended 31 March 2014, Bliss GVS Pharma's R&D center, received approval from Government of India's Department for Scientific & Industrial Research (DSIR).

During the year under review, the company invested in 51% share capital of Lifeon Labs Pvt Ltd.

During the year under review, Bliss GVS Pharma faced challenges in Ghana, where delays in registration resulted in adverse regulatory action. However, the company took quick, corrective measures to resolve these issues. The business is now backing on track in Ghana.

During the year ended 31 March 2015, Bliss GVS Pharma formed a new company Asterisk Lifesciences Limited as a wholly owned foreign subsidiary in United Kingdom for the purpose of facilitating registrations and marketing of pharmaceutical formulations in the European continent.

During the financial year ended 31 March 2016, Bliss GVS Pharma continued to grow in various geographies in Kenya, Nigeria and France. Such growth was mainly achieved due to contract manufacturing and consistent focus on new product launch in Kenya and Nigeria.

Bliss GVS Pharma continued to strengthen its operations and creation of robust Quality Manufacturing operations during the year ended 31 March 2017,

The company's investment in managed healthcare services delivered encouraging results with the company procuring USD 111.40 mMillion contract from Aon. This presents a great platform for the unit to build on its recent success to successfully bid for other such contracts.

During the year ended 31 March 2018, Bliss GVS Pharma divested three subsidiaries viz. Lifeon Labs Private Limited, Bliss Indasi Lifescience Private Limited and Shree Salespack Private Limited and one materially significant step down subsidiary Bliss GVS Healthcare Limited, Nairobi to focus on its core pharmaceutical operations, which have been a steady source of growth.

As on 31 March 2019,the company has one domestic and 3 overseas subsidiaries.

During the FY2020,the Company has completed the commissioning & qualification of Phase-I for its new state of the art multi-product facility situated at Palghar East in Maharashtra. This is the largest manufacturing unit of the Company in terms of planned production capacity when completed. It is equipped with state-of-the-art process equipment & utilities with a large part of the manufacturing process automated for enhanced levels of productivity, efficiency & compliance while reducing manual intervention. The unit is spread on an overall area of about 200,000 sq. ft. and is intended to further augment the production capacities for the Company.

The Company has 4 wholly owned subsidiaries and 3 step-down subsidiaries as on 31 March 2020. During the year, ECO Rich Cosmetics India Private Limited discontinued or ceased to be a step-down subsidiary of the Company consequent to loss of control. The Company's wholly owned subsidiary Bliss GVS Clinic HealthCare Pte. Ltd. situated at Singapore became a material subsidiary for the Company during the financial year 2019-2020.

Bliss GVS Pharma Share Price

Bliss GVS Pharma share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Bliss GVS Pharma Market Cap

Market capitalization of Bliss GVS Pharma indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Bliss GVS Pharma is valued compared to its competitors.

Bliss GVS Pharma PE Ratio

Bliss GVS Pharma PE ratio helps investors understand what is the market value of each stock compared to Bliss GVS Pharma 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Bliss GVS Pharma PEG Ratio

The PEG ratio of Bliss GVS Pharma evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Bliss GVS Pharma ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Bliss GVS Pharma generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Bliss GVS Pharma ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Bliss GVS Pharma in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Bliss GVS Pharma Total Debt

Total debt of Bliss GVS Pharma shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Bliss GVS Pharma Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Bliss GVS Pharma compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Bliss GVS Pharma CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Bliss GVS Pharma over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Bliss GVS Pharma Technical Analysis

Technical analysis of Bliss GVS Pharma helps investors get an insight into when they can enter or exit the stock. Key components of Bliss GVS Pharma Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Bliss GVS Pharma shares often struggle to rise above due to selling pressure.

Bliss GVS Pharma Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Bliss GVS Pharma ’s financial health and profitability.

Bliss GVS Pharma Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Bliss GVS Pharma Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Bliss GVS Pharma Financials

The financials of Bliss GVS Pharma provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Bliss GVS Pharma Profit and Loss Statements

The profit and loss statement of Bliss GVS Pharma highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Bliss GVS Pharma .

Bliss GVS Pharma Balance Sheet

The balance sheet presents a snapshot of Bliss GVS Pharma ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Bliss GVS Pharma Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App

Download the App